These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448 [TBL] [Abstract][Full Text] [Related]
5. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096 [TBL] [Abstract][Full Text] [Related]
6. Interferon-Induced Transmembrane Protein 1 (IFITM1) Is Downregulated in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. Park GH; Park E; Lee SJ; Lim K; Kim J; Park JE; Jeong SY Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273214 [TBL] [Abstract][Full Text] [Related]
7. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms. Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965 [TBL] [Abstract][Full Text] [Related]
8. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1. Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037 [TBL] [Abstract][Full Text] [Related]
10. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Ahsan S; Ge Y; Tainsky MA Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873 [TBL] [Abstract][Full Text] [Related]
11. MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Brundage ME; Tandon P; Eaves DW; Williams JP; Miller SJ; Hennigan RH; Jegga A; Cripe TP; Ratner N Oncogene; 2014 Dec; 33(49):5626-36. PubMed ID: 24509877 [TBL] [Abstract][Full Text] [Related]
12. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK. Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125 [TBL] [Abstract][Full Text] [Related]
14. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST. Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222 [TBL] [Abstract][Full Text] [Related]
15. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Katz D; Lazar A; Lev D Expert Rev Mol Med; 2009 Oct; 11():e30. PubMed ID: 19835664 [TBL] [Abstract][Full Text] [Related]
16. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341 [TBL] [Abstract][Full Text] [Related]
17. The promise of signal transduction in genetically driven sarcomas of the nerve. Kim A; Pratilas CA Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862 [TBL] [Abstract][Full Text] [Related]
18. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. Subramanian S; Thayanithy V; West RB; Lee CH; Beck AH; Zhu S; Downs-Kelly E; Montgomery K; Goldblum JR; Hogendoorn PC; Corless CL; Oliveira AM; Dry SM; Nielsen TO; Rubin BP; Fletcher JA; Fletcher CD; van de Rijn M J Pathol; 2010 Jan; 220(1):58-70. PubMed ID: 19890883 [TBL] [Abstract][Full Text] [Related]
19. An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors. Patel AV; Chaney KE; Choi K; Largaespada DA; Kumar AR; Ratner N EBioMedicine; 2016 Jul; 9():110-119. PubMed ID: 27333032 [TBL] [Abstract][Full Text] [Related]